BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BLU-924 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BLU-924\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07629960-2404@assetmemo.bio
DTSTAMP:20261121T005805Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:BLU-924: Phase 1/2 readout est. (NCT07629960)
DESCRIPTION:BLU-924\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Fir
 st-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harborin
 g KRAS Mutations\nEstimated primary completion: September 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/blu-924#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07629960
URL:https://assetmemo.bio/drug/blu-924#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
